Neurocrine Biosciences

REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...

SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...

TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....

Brisbane, California, USA, April 6, 2026 First-in-Human Study Targets Inflammation Pathways In a significant milestone for clinical-stage biotech innovation,...

San Diego & Redwood City, California, USA, April 6, 2026 Strategic Acquisition Strengthens Rare Disease Leadership In a major...